title: Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
authors.affiliation: Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Hill
authors.forename: Paolo
authors.initials: P
authors.lastname: Caimi
authors.forename: Tammy
authors.initials: T
authors.lastname: Kindwall-Keller
authors.forename: Becky
authors.initials: B
authors.lastname: Habecker
authors.forename: Matt
authors.initials: M
authors.lastname: Kalaycio
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009588:Nitrogen Mustard Compounds; D000074323:Alemtuzumab; D000069461:Bendamustine Hydrochloride; D014740:Vidarabine; C024352:fludarabine
keywords: CLL; chemotherapy; monoclonal antibodies